Department of Hypertension and Nephrology, NTT Medical Centre Tokyo, 5-9-22, Higasi-Gotanda, Shinagawa-ku, Tokyo, 141-8625, Japan.
BMC Infect Dis. 2019 Jul 15;19(1):625. doi: 10.1186/s12879-019-4193-y.
Visceral disseminated varicella zoster virus (VDVZV) infection is a rare disease with a high mortality rate (55%) in immunocompromised patients, but it is not yet widely recognized in the field of nephrology. We report a case of VDVZV contracted during immunosuppressive therapy for membranous nephropathy.
A 36-year-old woman was diagnosed with membranous nephropathy and was being treated with immunosuppressive therapy consisting of 60 mg/day prednisolone, 150 mg/day mizoribine, and 150 mg/day cyclosporine. Nephrosis eased; therefore, the prednisolone dosage was reduced. However, 50 days after starting immunosuppressive therapy, the patient suddenly developed strong and spontaneous abdominal pain, predominantly in the epigastric area, without muscular guarding or rebound tenderness. Blood data indicated neutrophil-dominant elevated white blood cell count, reduced platelet count, elevated transaminase and lactate dehydrogenase, slightly increased C-reactive protein, and enhanced coagulability. Abdominal computed tomography revealed a mildly increased enhancement around the root of the superior mesenteric artery with no perforation, intestinal obstruction, or thrombosis. The cause of the abdominal pain was unknown, so the patient was carefully monitored and antibiotic agents and opioid analgesics administered. The following day, blisters appeared on the patient's skin, which were diagnosed as varicella. There was a marked increase in the blood concentration of VZV-DNA; therefore, the cause of the abdominal pain was diagnosed as VDVZV. Treatment with acyclovir and immunoglobulin was immediately started, and the immunosuppressive therapy dose reduced. The abdominal pain resolved rapidly, and the patient was discharged 1 week after symptom onset.
This patient was VZV-IgG positive, but developed VDVZV due to reinfection. Abdominal pain due to VDVZV precedes the skin rash, which makes it difficult to diagnose before the appearance of the rash, but measuring the VZV-DNA concentration in the blood may be effective. Saving the patient's life requires urgent administration of sufficient doses of acyclovir and reduced immunosuppressive therapy.
内脏播散性水痘带状疱疹病毒(VDVZV)感染是一种罕见疾病,在免疫功能低下的患者中的死亡率(55%)很高,但在肾脏病领域尚未得到广泛认识。我们报告了一例在膜性肾病免疫抑制治疗期间感染 VDVZV 的病例。
一名 36 岁女性被诊断为膜性肾病,接受免疫抑制治疗,包括 60mg/天泼尼松龙、150mg/天米佐米滨和 150mg/天环孢素。肾病缓解;因此,减少了泼尼松龙剂量。然而,在开始免疫抑制治疗后 50 天,患者突然出现强烈而自发的腹痛,主要在上腹部,无肌肉紧张或反跳痛。血液数据表明中性粒细胞占主导地位的白细胞计数升高、血小板计数降低、转氨酶和乳酸脱氢酶升高、C-反应蛋白略高和凝血功能增强。腹部计算机断层扫描显示肠系膜上动脉根部增强轻度增加,无穿孔、肠梗阻或血栓形成。腹痛原因不明,因此患者被密切监测并给予抗生素和阿片类镇痛药。第二天,患者皮肤上出现水疱,诊断为水痘。VZV-DNA 血浓度明显升高;因此,腹痛的原因诊断为 VDVZV。立即开始使用阿昔洛韦和免疫球蛋白治疗,并减少免疫抑制治疗剂量。腹痛迅速缓解,患者在症状出现后 1 周出院。
该患者 VZV-IgG 阳性,但由于再感染而发生 VDVZV。VDVZV 引起的腹痛先于皮疹出现,因此在皮疹出现前难以诊断,但测量血液中的 VZV-DNA 浓度可能有效。挽救患者生命需要紧急给予足够剂量的阿昔洛韦并减少免疫抑制治疗。